Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danicopan add-on therapy in PNH with extravascular hemolysis
NCT04469465Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Dec 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of danicopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Alexion Pharmaceuticals. Started Dec 2020; status: completed.
02
Drugs
danicopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT04469465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04469465.